Navigation Links
Gene therapy extends survival in an animal model of spinal muscular atrophy
Date:5/22/2014

New Rochelle, NY, May 22, 2014To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA. A new study demonstrating that enough copies of the SMN1 gene can be delivered to the spinal cord motor neurons to extend the survival of the treated animals is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

Marco Passini and coauthors from Genzyme (Framingham, MA), University of California San Francisco, Emory University School of Medicine (Atlanta, GA), and Georgetown University Medical Center (Washington, DC) used an adeno-associated viral vector as the delivery vehicle to transport copies of the SMN1 gene into motor neurons in the spinal cord via intrathecal delivery. They report on the effectiveness of restoring the levels of functional SMN protein in normal pig and non-human primate SMA models that would predict efficacy based on gene transfer with the same vector in an authentic mouse model of SMA in the article "Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9Survival Motor Neuron 1 for Spinal Muscular Atrophy."

"This is a very promising and thorough set of preclinical studies that supports rapid translation to the clinic," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Novel RNAi therapy silences mutated Huntingtons disease gene and reduces symptoms
2. Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS
3. Chemotherapy timing is key to success
4. Soy sauce molecule may unlock drug therapy for HIV patients
5. Autologous stem cell therapy improves motor function in chronic stroke victims
6. Loss of memory in Alzheimers mice models reversed through gene therapy
7. Radiation therapy for cervical cancer increases risk for colorectal cancer
8. Friedreichs ataxia -- an effective gene therapy in an animal model
9. New Penn-designed gel allows for targeted therapy after heart attack
10. Natural plant compounds may assist chemotherapy
11. Immunotherapy data heralds new era of lung cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy extends survival in an animal model of spinal muscular atrophy
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... essential question confronting neuroscientists and computer vision researchers alike is ... Introspectively, we know that the human brain solves this ... something to know what it is. But teaching a ... In research published this fall in the Public Library of ...
... Hay fever (runny nose, sneezing, itchy eyes) is caused by ... These tiny grains bring misery to sufferers through spring and ... weather reports to help sufferers prepare. However new research published ... Allergy shows that, regardless of medication and other allergies, ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:Do you see what I see? 2Do you see what I see? 3Get ready for spring - hay fever worse in spring than summer 2
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... (Nasdaq: KNDL ), a,leading, global full-service clinical ... Chief Financial Officer Karl,"Buzz" Brenkert, III will participate ... The conference will be held at the,Loews Miami ... Kendle,s,presentation is scheduled for Tuesday, March 18 at ...
... March 14 Quest Diagnostics,Incorporated (NYSE: DGX ... and services, announced that it is scheduled to ... Conference on,Wednesday, March 19, 2008, at The Loews ... is scheduled to begin at 9:00 a.m.,Eastern Time., ...
... March 14 Wyeth (NYSE: WYE ),announced today ... Annual,Global Healthcare Conference on Wednesday, March 19, 2008 at ... M. Mahady, Senior Vice,President, Wyeth and President, Wyeth Pharmaceuticals., ... at, http://www.wyeth.com and available for replay following the ...
Cached Biology Technology:Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2
...
... Cosmid Cloning Kit enables you to prepare, ... unbiased primary cosmid library of genomic DNA ... sublibraries. High efficiency cosmid library construction is ... protocols. First, genomic DNA is randomly sheared ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... Analyzer is a revolutionary multi-capillary electrophoresis system ... platform. It integrates sample loading, electrophoresis, and ... improving the workflow and increasing the productivity ... Benefits of using HDA system are:, ...
Biology Products: